Dihydrotestosterone increases the risk of bladder cancer in men
- 238 Downloads
Men are at a higher risk of developing bladder cancer than women. Although the urinary bladder is not regarded as an sex organ, it has the potential to respond to androgen signals. The mechanisms responsible for the gender differences remain unexplained. Androgen receptor (AR) after binding with 5α-dihydrotestosteron (DHT) undergoes a conformational change and translocates to nucleus to induce transcriptional regulation of target genes. However androgen/AR signaling can also be activated by interacting with several signaling molecules and exert its non-genomic function. The aim of present study was to explain whether the progression of bladder cancer in men is dependent on androgen/AR signaling. Studies were carried out on human bladder cancer cell lines: HCV29, T24, HT1376 and HTB9. Bladder cancer cells were treated for 48 h with 10 nM DHT or not, with replacement after 24 h. Expression of cell signaling proteins, was analyzed using Western Blot and RT-PCR. Subcellular localization of protein was studied using the ProteoExtract Subcellular Proteome Extraction Kit and Western blot analysis. We showed that DHT treatment significantly increased AR expression in bladder cell line HCV29. We also observed DHT-mediated activation of Akt/GSK-3β signaling pathway which plays a central role in cancer progression. Presented results also show that androgen/AR signaling is implicated in phosphorylation of eIF4E which can promote epithelial–mesenchymal transition (EMT). We indicate that AR plays an essential role in bladder cancer progression in male patients. Therefore, androgen-activated AR signaling is an attractive regulatory target for the inhibition or prevention of bladder cancer incidence in men.
KeywordsBladder cancer Androgen receptor Akt GSK-3β eIF4E
Bladder cancer (BC) is currently the one of the very widespread genitourinary tract malignancy, the fifth most common cancer in men and the nineteenth in women [1, 2]. Different environmental and lifestyle factors, such as industrial chemicals or cigarette smoking, have been believed as the reasons for sex-related differences. Although the urinary bladder is not regarded as an sex organ, it has the potential to respond to androgen signals, because is derived from the endoderm of the urogenital sinus which expresses the AR . AR signaling was shown as the crucial oncogenic driver of prostate cancer, it is also significantly associated with tumor progression in other solid tumors, such as lung, kidney, breast and bladder cancers [4, 5]. The mechanisms responsible for the gender differences remain unclear but AR signaling pathway has been proposed as an important factor that is involved in the development and progression of BC. Studies in animal models evidence that AR in urothelium may play a crucial role in cancerogenesis and progression of BC . Shiota et al. showed that men with prostate cancer who underwent androgen deprivation therapy had a lower risk of development of bladder cancer in comparison to those undergoing surgery or radiotherapy, only . Also, Fahmy et al. described high incidence of prostatic adenocarcinoma in cystoprostatectomy specimens undergone for bladder urothelial carcinoma .
Androgen receptor in the cytoplasm occurs in the complex with heat shock proteins, and upon binding DHT, AR is released from heat shock proteins and translocates to nucleus to induce transcriptional regulation of target genes. This AR-signaling pathway is known as the genomic pathway. However, androgen/AR signaling can also be activated by an alternative mechanism independent on androgen binding that includes its phosphorylation by kinases [9, 10]. Studies on prostate cancers showed that binding of androgen to AR in the cytoplasm may initiate signal transduction pathways to regulate cellular proliferation and migration, known as non-genomic pathway, that requires neither AR nuclear translocation nor DNA binding [11, 12, 13]. In addition, non-genomic AR signaling may be mediated by a membrane-bound AR [14, 15]. Signaling molecules activated by AR in transcription-independent manner includes Src, Ras, MAPK, Akt, PKC, PLC, EGFR and other secondary messenger proteins . It is possible that non-genomic activity influences AR genomic activity and that of other nuclear receptor.
Androgen receptor has been detected in human BC in a number of studies but it is not clear whether its expression level is important in bladder cancer progression [9, 10, 16, 17]. The data suggest that AR expression is more often upregulated in early stages of disease than in advanced stages of BC . Because men have higher circulating level of androgen than females and AR can be variably expressed also in female tumors, probably that combination of AR expression level and elevated androgen signaling play the essential role in gender distinction characterizing BC.
The aim of present study was to elucidate the mechanism of androgen/AR signaling in promotion of bladder cancer in male patients.
Materials and methods
HCV29 (nonmalignant transitional epithelial cells of the ureter), T24 (transitional cancer cells of the urine bladder), HT1376 (urinary bladder carcinoma, grade III) and HTB9 (urinary bladder cancer grade II) cell lines were obtained from American Type Culture Collection. These cell lines were then purchased from ATCC by M. Lekka’s lab and authenticated by short tandem repeat analysis by LGC Standard. All cell lines are examined annually for mycoplasma infection by PCR method. The cells were cultured in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS) (Gibco) and 1% penicillin/streptomycin .
Cell culture treatment
Bladder cancer cells were treated for 48 h with DHT, 10 nM, (Sigma-Aldrich) with replacement after 24 h. Dihydrotestosterone was prepared at a stock concentration of 0.2 M in ethanol (Sigma-Aldrich). A dose of 10 nM in serum-free Opti-MEM (Gibco) was used as the physiological dose capable of effectively activation of AR expression. As the vehicle control, bladder cells were cultured with 0.1% ethanol. Since there were no differences between ethanol-treated cells (not shown) and untreated cells, the latter were selected as control cells in each experiment. Bladder cancer cells 24 h after seeding were treated for 0.5 h or 1 h with 10 nM DHT, 0.1% ethanol as a control in serum-free Opti-MEM and afterwards used to study non-nuclear AR signaling.
Preparation of cytoplasmic, membrane, nuclear and cytoskeletal cell lysates
Cytoplasmic, membrane, nuclear and cytoskeletal extracts were prepared using the ProteoExtract® Subcellular Proteome Extraction Kit (MERCK Millipore) by following the manufacturer’s instructions.
Western blot analysis
Cells lysis and western blot were carried out as previously described . Antibodies for: ILK, Akt, E-cadherin, Vimentin, GSK-3β, phospho-GSK-3β (Y216), β-catenin (all Transduction Laboratories BD), AR, Src, phospho-Src (Y416), phospho-ERK (T202/Y204), phospho-Akt (S473), phospho-GSK-3β (S9), D1, D3 and phospho-eIF4E (S209) (all Cell Signaling Technology Inc.), N-cadherin (R&D) and β-actin, ZEB1, (all Sigma) SNAIL (ABGENT), Calnexin, HSP-90 (all Calbiochem) were used to detect indicated proteins. The presence of the primary antibody was revealed with horseradish peroxidase-conjugated secondary antibodies diluted 1:2000 (Cell Signaling Technology Inc) and visualized with an enhanced chemiluminescence detection system (Bio-Rad) as previously described . β-Actin served as a loading control. All immunoblots were stripped with stripping buffer containing 25 mM glycine–HCl, pH 2, 1% (wt/v) SDS for 30 min, and incubated in antibody against β-actin (dilution, 1:3000; Sigma-Aldrich), which served as a loading control. To obtain quantitative results, immunoblots were scanned using the public domain ImageJ software (National Institute of Health). Each data point was normalized against its corresponding actin data point.
In vitro wound healing/migration assay
The in vitro model of wound healing was used to compare the migration and proliferation potential of bladder cancer cell lines in presence or absence of DHT. For wound healing assay, cells were grown in RPMI-1640 medium supplemented with 10% fetal calf serum in 24-well plates until confluent. A small linear scratch was created in the confluent monolayer by gently scraping with sterile 1 ml pipette tip. The cells were washed with medium to remove cellular debris and serum-free Opti-MEM media with 10 nM DHT or 0.01% ethanol as control were added. Twenty-four hours later, images of the migrated cells were taken using digital camera (Nikon), connected to the inverted microscope. The assay was repeated thrice in duplicate. Wound area was calculated by manually tracing the cell-free area in captured images using the public domain ImageJ software. The migration rate was expressed as the percentage of wound closure.
RNA extraction, cDNA synthesis and RT-PCR analysis
RNA extraction, preparation of cDNA and RT-PCR reaction were carried out as previously described . The following specific primers were used:
GAPDH; (59 °C, 30 s): 5′CACCGCCTCGGCTTGTCACAT 3′ and 5′CTGCTGTCTTGGGTGCATTGC3′;
N-CADHERIN; (60 °C, 40 s): 5′GTGCCATTAGCCAAGGGAATTCAGC3′ and 5′CGAGGATACTCACCTTGTCCTTGCG 3′;
E-CADHERIN; (60 °C, 40 s): 5′GCCAAGCAGCAGTACATTCTACACG3′ and 5′GTCGTTCTTCACGTGCTCAAAATCC3′;
AR; (58, 30 s): 5′ TGTCAACTCCAGGATGCTCTACTT3′ and 5′ATTCGGACACACTGGCTGTACA3′
The PCR reaction products were separated electrophoretically on 2% agarose gel and visualized with ethidium bromide.
Each variable was tested using the Shapiro–Wilk W test for normality. Homogeneity of variance was assessed with Levene’s test. Since the distribution of the variables was normal and the values were homogeneous in variance, all statistical analyses were performed using one-way analysis of variance (ANOVA) followed by Dunnett’s post hoc comparison test to determine which values differed significantly from controls. The analysis was made using Statistica software (StatSoft). Data were presented as mean ± SD. Data were considered statistically significant at p* < 0.05, p** < 0.01, p*** < 0.001.
Expression of AR in human bladder and cancer cell lines
AR expression was found to be the strongest in the transitional epithelial cells HCV29 and in transitional cell carcinoma T24. Both cell lines have been derived from men as well as more aggressive cell line HTB9 from grade II. The expression of AR was not found in HTB9 and in cell line HT1376 from grade III carcinoma, which is of female origin. These results suggested that AR expression is higher in non-cancer stage and in the early stages of bladder cancer progression, and likely decreases as the disease progresses.
Effects of DHT on androgen receptor expression in bladder cell lines
Non-nuclear AR signaling
Androgen mediates AR translocation
Androgen receptor usually locates in cytoplasm in complex with heat shock protein. Ligand-activated AR is known to translocate to the nucleus and subsequently activates transcription of several target genes. Cytoskeletal proteins facilitate nuclear targeting of AR. We checked intracellular localization of AR in the presence and absence of DHT. Western blot analysis of subcellular fraction (Fig. 4) shown that, without ligand, AR is located largely in the cytoplasm, but after incubation with DHT, AR is still present in cytoplasm but also undergoes preferentially to cytoskeletal fraction and membrane fraction and small amount are present in nucleus. These results suggest that DHT in bladder cancer activates not only the canonical AR signaling but also the non-genomic AR signaling.
AR and Akt interact in lipid rafts in membrane fraction
Androgen receptor non-genomic signaling pathway can start as well at the plasma membrane. AR associates with plasma membrane lipid rafts and facilitates AR activation of these pathways. AR can localize to lipid rafts and interacts with and activate Akt independently of PI3K, which is usually required for downstream activation of Akt. Western blot analysis of subcellular fraction has shown visible increase of Akt level likewise AR protein in membrane fraction after androgen stimulation in comparison to control non-stimulated cells in both bladder cell lines HCV29 and T24 (Fig. 4).
Androgen/AR signaling modulates translation initiation
Effect of AR on EMT markers in bladder
AR influences would healing
Both genetic and environmental factors contribute to the initiation, progression and development of urinary bladder cancer (UBC). Using molecular classification in bladder cancer cell line models, we recognized that bladder cell lines showed differential expression of androgen receptor in male origins cell lines and responded differently to androgen stimulation. We found that nonmalignant transitional epithelial cells and transitional cell carcinoma had higher levels of AR expression compared to high-grade or muscle-invasive tumor cell lines. Also, immunohistochemistry study by Miyamoto et al. or Boorjian and colleagues indicated that down-regulated AR expression in UBC may be associated with tumor progression [22, 23]. However, other studies presented conflicting data . Additionally, we observed very significant increase in androgen protein level after supplementation of DHT only in nonmalignant and carcinoma transitional cells. Androgens are known important regulators of AR mRNA and protein through transcriptional and post-transcriptional mechanisms. AR is ligand-dependent transcriptional factor that regulates gene expression, ligand binding profoundly increases AR stability and this stabilization is relatively unique to AR as other steroid receptors undergo hormone-mediated downregulation . AR increases more than three times in the presence of androgen in prostate cell line LNCaP. The half-life of ligand-bound AR protein levels is also sensitive to regulation by cap-dependent mRNA translation . Mikkonen et al. have shown that androgen administration significantly upregulated AR expression in murine lung and modified gene expression in a human lung cancer cell line . Higher level of androgens in men than in women may be a reason for increased AR protein level and intensification of AR signaling especially at early stages of tumor initiation and progression of BC. After androgen stimulation in both cell lines HCV29 and T24, we observed AR translocation to the nucleus and also increased AR amount in cytoskeletal fraction. Interaction of AR with cytoskeletal proteins facilitates nuclear targeting of AR and probably increased of AR transcriptional activity which plays important role in G1/S phase transition. The cytoplasmic action of AR is observed also in non-prostate cells, such as fibroblast, where the level of AR is relatively low, and AR translocation in response to androgen is not observed . However, non-genomic AR signaling also promotes cell proliferation and survival. Activation of AR signaling causes the regulation of numerous signaling pathways PI3K/Akt, Src and MAPK/ERK that in turn regulate cell proliferation. In addition, non-genomic effects of DHT can manifest independently, or in tandem, with the other genomic effects, to initiate androgen responses.
Activation of AR causes the regulation of numerous signaling pathways that in turn regulate EMT, which is early step in metastatic progression. EMT is a process by which epithelial cells lose their epithelial features and obtain a mesenchymal phenotype. Loss of E-cadherin expression and induction of N-cadherin expression is a hallmark of the EMT process . A reduction or loss in expression of E-cadherin and the increase of N-cadherin expression in bladder cancer have been shown to be important in cancer progression . Androgen-mediated AR signaling was also described to induce EMT in bladder cancer cells [34, 35]. Our data demonstrate that AR signaling can regulate the “cadherin switch” in bladder nonmalignant transitional epithelial cells and cancer cells. Robichaud et al. reported that EMT is regulated also by cap-dependent translation in mammary tumor model. They showed that eIF4E phosphorylation on Ser 209 is important for EMT and invasion . It is also known that eIF4E activity is essential for controlling proliferation and invasion in bladder cancer . Availability and phosphorylation of eIF4E are regulated by various upstream kinases and one of them is Akt. In our study, we found the slight increase of phosphorylation of eIF4E after DHT stimulation of androgen signaling. Considering how important factor is translational control in tumorigenesis, our result is not without significance.
It has been suggested that muscle-invasive bladder cancers are initially androgen sensitive for their growth but the sensitivity is lost during the progression due to activation of set of genes involved in metastasis. Activation of androgen/AR genomic and non-genomic signaling probably is not a driver in male bladder oncogenic transformation, but is a major player in progression of those cancers. Therefore, androgen-activated AR signaling is an attractive regulatory target for the inhibition or prevention of bladder cancer incidence in men.
This work was supported by a grant from Ministry of Science & Higher Education (MNiSW) through Jagiellonian University Medical College K/ZDS/006459.
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 8.Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Stenzl A, Gakis G. Clinicopathological features and prognostic value of incidental prostatic adenocarcinoma in radical cystoprostatectomy specimens: a systematic review and meta-analysis of 13140 patients. J Urol. 2017;197:385–90.CrossRefGoogle Scholar
- 11.Liao RS, Ma S, Miao L, Li R, Yin Y, Raj GV. Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation. Transl Androl Urol. 2013;2:187–96. https://doi.org/10.3978/j.issn.2223-4683.2013.09.07.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.